The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as ...

Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients

“…By excluding ESRD costs in the main analysis but including them in a separate analysis our results can be widely compared. The cost-effectiveness with inclusion of future ESRD costs was comparable to other studies focusing on systemic anticoagulation [61], hyperphosphataemia [60], secondary hyperparathyroidism [59] and anaemia [62].…”

“…Our analysis confirms these earlier findings and underscores the relevance of the debate by calculating that inclusion of dialysis and renal transplant care costs double the ICER of the screen and treat strategy. Several studies in ESRD patients did not include the future costs of ESRD care [56][57][58], whereas others analysed therapies both with and without future costs [59][60][61]. By excluding ESRD costs in the main analysis but including them in a separate analysis our results can be widely compared.…”

Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism

“…111 Another cost analysis derived from the OPTIMA trial data also appears to favor cost-effectiveness of cinacalcet in five European countries, despite differences in healthcare systems and economic wealth. 112 This is contrary to the previous UK-based report 113 and ACHIEVE trial data-based simulation model, which found that cinacalcet therapy was more costly. 114 Rogerri et al analyzed FARO study data and suggested that paricalcitol treatment alone was significantly less expensive than combined with cinacalcet regardless of baseline severity and control of SHPT.…”

Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

“…In all other patients, parathyroidectomy is the most cost-effective treatment [27] . The cost-effectiveness of long-term cinacalcet treatment was questioned by Garside et al [28] as well, who, nevertheless, used a high mean daily dose of 94 mg/day for their analysis.…”